• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side‐Effect Profiles
ABSTRACT Pharmacotherapy directed toward reducing body weight may provide benefits for both curbing obesity and lowering the risk of obesity‐associated co‐morbidities. However, many weight loss medications have been withdrawn from the market due to serious adverse effects. Examples include pulmonary hypertension (aminorex), cardiovascular toxicity, e.g. flenfluramine‐induced valvopathy, stroke (phenylpropanolamine), excess non‐fatal cardiovascular events (sibutramine), and neuro‐psychiatric issues (rimonabant ‐ approved in Europe, but not in the US). This negative experience has helped mold the current drug dev...
Source: Diabetes, Obesity and Metabolism - March 1, 2016 Category: Endocrinology Authors: Andrew J. Krentz, Ken Fujioka, Marcus Hompesch Tags: REVIEW ARTICLE Source Type: research

Pediatric obesity: Causes, symptoms, prevention and treatment.
Authors: Xu S, Xue Y Abstract Pediatric or childhood obesity is the most prevalent nutritional disorder among children and adolescents worldwide. Approximately 43 million individuals are obese, 21-24% children and adolescents are overweight, and 16-18% of individuals have abdominal obesity. The prevalence of obesity is highest among specific ethnic groups. Obesity increases the risk of heart diseases in children and adults. Childhood obesity predisposes the individual to insulin resistance and type 2 diabetes, hypertension, hyperlipidemia, liver and kidney diseases and causes reproductive dysfunction in adults. Obe...
Source: Experimental and Therapeutic Medicine - February 4, 2016 Category: Journals (General) Tags: Exp Ther Med Source Type: research

Cardiovascular effects of current and future anti-obesity drugs.
Abstract The prevalence of obesity increases and is associated with increases in co-morbidities e.g. type 2 diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, heart disease, stroke, asthma, several forms of cancer, depression, and may result in reduction of expected remaining lifespan. We have reviewed the adverse effects on the cardiovascular system of anti-obesity drugs now retracted from the market as well as the cardiovascular profile of current drugs and potential pathways which are considered for treatment of obesity. Fenfluramine, and sibutramine were withdrawn due to increased cardiovascular ...
Source: Current Vascular Pharmacology - May 24, 2014 Category: Drugs & Pharmacology Authors: Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U Tags: Curr Vasc Pharmacol Source Type: research

Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial
Conclusion: Bilirubin was not a risk-factor independent from other traditional cardiovascular risk-factors in our population.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - February 18, 2014 Category: Nutrition Authors: M.E. Jørgensen, C. Torp-Pedersen, N. Finer, I. Caterson, W.P.T. James, U.F. Legler, C. Andersson Tags: Liver abnormalities, diabetes and cardiovascular risk Source Type: research

A safe, effective diet pill - the elusive holy grail
Trade in illegal, ineffective drugs flourishes as pharmaceutical industry repeatedly fails to produce successful pillAttempts to invent a safe and effective diet pill have foundered time and again, allowing the internet trade in illegal and ineffective herbal supplements and dangerous drugs, such as DNP, to flourish.A successful diet pill could make billions for the pharmaceutical industry, but efforts to date have ended in disaster, with patients harmed, drugs banned and massive compensation paid out.Fen-phen, an appetite suppressant, was the most spectacular failure. It was withdrawn in the US in 1997 after causing wides...
Source: Guardian Unlimited Science - January 14, 2014 Category: Science Authors: Sarah Boseley Tags: The Guardian Diets and dieting Drugs trade Healthcare industry World news Pharmaceuticals industry & wellbeing Health policy Society Politics UK news Life and style Public services policy Business Science Source Type: news

Orlistat reduces weight but its cost-effectiveness remains unclear
This study aimed to evaluate the effectiveness and cost effectiveness of three pharmacological interventions (orlistat, sibutramine and rimonabant) in obese patients in...
Source: Evidence-Based Nursing - March 8, 2013 Category: Nursing Authors: Veerman, L. Tags: Health policy, General practice / family medicine, Drugs: cardiovascular system, Stroke, Obesity (nutrition), Health service research, Health education, Obesity (public health) Primary healthcare Source Type: research